Vaxine
Vaxine Pty Ltd is an Australian biotechnology company based in Adelaide, South Australia, specializing in the development of innovative vaccines and immunotherapies. Over the past 20 years, Vaxine has developed a broad portfolio of vaccines including those against Covid-19, influenza, hepatitis B, Japanese encephalitis, and immunotherapies for allergy and cancer. The company leverages its patented Advax™ delta inulin polysaccharide adjuvant platform and artificial intelligence for rapid drug design to enhance vaccine efficacy. Vaxine has achieved multiple world firsts such as the first AI-designed vaccine and the first approved recombinant spike protein vaccine. Their business model focuses on vaccine development and clinical trials, with a strong scientific research foundation and global health impact. Vaxine has received regulatory approvals, including pediatric approval for its Covid-19 vaccine in the Middle East, and is actively conducting clinical trials for vaccines including an Alzheimer’s disease vaccine and cancer immunotherapy.
Vaxine
Vaxine Pty Ltd is an Australian biotechnology company based in Adelaide, South Australia, specializing in the development of innovative vaccines and immunotherapies. Over the past 20 years, Vaxine has developed a broad portfolio of vaccines including those against Covid-19, influenza, hepatitis B, Japanese encephalitis, and immunotherapies for allergy and cancer. The company leverages its patented Advax™ delta inulin polysaccharide adjuvant platform and artificial intelligence for rapid drug design to enhance vaccine efficacy. Vaxine has achieved multiple world firsts such as the first AI-designed vaccine and the first approved recombinant spike protein vaccine. Their business model focuses on vaccine development and clinical trials, with a strong scientific research foundation and global health impact. Vaxine has received regulatory approvals, including pediatric approval for its Covid-19 vaccine in the Middle East, and is actively conducting clinical trials for vaccines including an Alzheimer’s disease vaccine and cancer immunotherapy.